INCYTE CORP business relationships

“These include OLUMIANT (baricitinib), which is licensed to our collaborative partner Eli Lilly and Company ("Lilly"), and JAKAVI (ruxolitinib) and TABRECTA (capmatinib), which are licensed to Novartis.” SEC filing

“Collaboration and License Agreement entered into as of November 24, 2009, by and between the Company and Novartis International Pharmaceutical Ltd. (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019).” SEC filing

“Our collaborators Novartis and Lilly are affected by similar considerations for the drugs that they market and for which we may receive royalties.” SEC filing

“Royalty revenues on commercial sales for JAKAVI and TABRECTA by Novartis are estimated based on information provided by Novartis.” SEC filing

“We have licensed to Novartis rights to ruxolitinib outside of the United States and worldwide rights to our MET inhibitor compounds, including TABRECTA, and licensed to Lilly worldwide rights to baricitinib.” SEC filing

“These include OLUMIANT (baricitinib), which is licensed to our collaborative partner Eli Lilly and Company ("Lilly"), and JAKAVI (ruxolitinib) and TABRECTA (capmatinib), which are licensed to Novartis.” SEC filing

“Royalty revenues on commercial sales for OLUMIANT by Lilly are estimated based on information provided by Lilly.” SEC filing

“Retifanlimab licensed from MacroGenics, Inc.” SEC filing

“In September 2021, we entered into a Collaboration and License Agreement with Syndax Pharmaceuticals, Inc. ("Syndax"), covering the worldwide development and commercialization of SNDX-6352 ("axatilimab").” SEC filing

“Tafasitamab licensed from Xencor, Inc.” SEC filing

“We are responsible for the sourcing and manufacturing of ZYNYZ together with our collaborator MacroGenics.” SEC filing

“In December 2016, we entered into a Collaboration and License Agreement with Merus N.V. ("Merus").” SEC filing

“Novartis licensed ruxolitinib from Incyte Corporation for development and commercialization in the indications of oncology, hematology and GvHD outside the US.” SEC filing

“Pursuant to the XOMA Royalty Purchase Agreement, we sold to XOMA 33 % of the future royalties and 10 % of the future milestones that we were entitled to receive from Incyte, excluding the $ 5.0 million milestone that we recognized in the three months ended September 30, 2018.” SEC filing

“Pursuant to our collaboration agreement with Incyte, we had exclusively licensed to Incyte monospecific antibodies targeting GITR, OX40, TIM-3 and LAG-3, as well as an additional undisclosed target.” SEC filing

“...commercial milestone payments we were then eligible to receive under our agreements with BMS, UroGen, Gilead, Merck and Incyte, (the "Covered License Agreements") (ii) 18.75 % of the royalties the Company receives under the Covered License Agreements; and (iii) a 2.625 % synthetic royalty on worldwi...” SEC filing

“In January 2015, we entered into a collaboration with Incyte to discover, develop, and commercialize novel immuno-therapeutics using our antibody platforms.” SEC filing

“...partnered oncology programs, including BMS-986442 (Bristol Myers Squibb), AGEN2373 (Gilead), INCAGN2385 and INCAGN2390 (Incyte), MK-4830 (Merck), and UGN-301 (UroGen Pharma) (collectively referred as "Agenus Partnered Programs"), and (ii) a synthetic 2.625 % royalty on future global net sales of Age...” SEC filing

“Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $ 150.0 million in 2017.” SEC filing

“We are eligible for tiered royalties of 15% to 24% on any global net sales (see Note 10, Royalty Monetization Arrangement, in our consolidated financial statements for further information about ZYNYZ royalties), and we have the option to co-promote retifanlimab with Incyte.” SEC filing

“In late January 2025, we launched Niktimvo for commercial sale in the U.S. in partnership with Incyte and in accordance with the collaboration agreement and license agreement with Incyte described below under the heading "Collaborations - Incyte Collaboration and License Agreement." Under the agreem...” SEC filing

“Our business currently depends heavily on our ability to successfully commercialize Revuforj in the United States and in other jurisdictions where we may obtain marketing approval as well as commercializing Niktimvo, with our collaboration partner Incyte, in the United States.” SEC filing

“We currently rely on third-party contract manufacturers as well as Incyte for all of our required raw materials, active pharmaceutical ingredients and finished product for our preclinical research, clinical trials, and commercial supply.” SEC filing

“We earned $10.2 million in estimated non-cash royalties from Incyte for the year ended December 31, 2025.” SEC filing

“The change was primarily driven by the revenue recognition associated with Alexion and Incyte license agreements as discussed below.” SEC filing

“Incyte: In June 2010, we entered into a Collaboration and License Agreement with MorphoSys AG, which was subsequently amended in 2012, 2020 and 2024 (as amended, the "MorphoSys Agreement").” SEC filing

“an immune checkpoint inhibitor manufactured by Incyte.” SEC filing

“We assessed the Option Agreement in accordance with ASC 606, Revenue from Contracts with Customer, and concluded that Incyte is a customer in the context of the Option Agreement.” SEC filing

“...li Lilly, Elicio Therapeutics, GenFleet Therapeutics (licensed to Verastem Oncology), Hyperway Pharmaceutical Co. Ltd., Incyte Corporation, Jiangsu Hansoh Pharmaceutical Group Co., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Kumquat Biosciences (licensed to Bayer), PAQ Therapeutics, Qilu Pharmaceutica...” SEC filing